Japan PMDA On-Site Audit Passed by Everlight Chemical API Plant!
According to the latest announcement by the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan, Everlight Chemical’s Active Pharmaceutical Ingredient (API) plant has successfully passed its 2026 on-site inspection. Under Japan’s notoriously stringent regulatory standards, this achievement not only recognizes Everlight’s rigorous approach to compliance and GMP management but also deepens international market trust in our brand.
Core Strengths and Product Portfolio
Products for the Japanese Market: Our API exported to Japan, Felodipine, is a long-acting calcium channel blocker (CCB) primarily used to treat hypertension and angina. In addition, we are actively promoting several ophthalmic drugs, aiming to successfully penetrate the Japanese market.
30 Years of Technological Heritage: In the face of intense competition from Chinese and Indian pharmaceutical manufacturers, Everlight has built a highly competitive technological barrier leveraged on our 30 years of R&D experience in prostaglandin drugs. Based on this expertise, we have expanded into diversified CDMO services—assisting clients in developing and manufacturing radiopharmaceuticals and plant-based APIs to jointly enter developed country markets.
Advancing Toward a World-Class Pharmaceutical Plant
Having successively passed physical on-site audits from the US FDA and Japan PMDA—two of the world’s most stringent regulatory authorities—means that Everlight’s API plant stands firmly on a solid GMP foundation.
Moving forward, we will continue to provide stable, reliable, and high-quality APIs, contributing to the global pharmaceutical industry!